Answers are grounded in this paper and cite their sources.
In a cohort of 483 high-risk patients treated with nirmatrelvir/ritonavir for COVID-19, 2 patients (0.4%) required hospitalization by day 30. Four patients (0.8%) experienced rebound of symptoms, which were generally mild, at a median of 9 days after treatment, and all resolved without additional COVID-19-directed therapy.
No takes yet. Share an insight, caveat, or question.
Ranganath et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: